We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Liver Transplantation and Metastatic Colo-rectal Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00294827
Recruitment Status : Active, not recruiting
First Posted : February 22, 2006
Last Update Posted : May 25, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Survival of colo-rectal cancer patients after liver transplantation.

Condition or disease Intervention/treatment Phase
Colo-rectal Cancer Procedure: Liver transplantation and colo-rectal cancer Phase 2

Detailed Description:
Survival, time to progression, other malignancy, side-effects, quality of life.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Liver Transplantation and Metastatic Colo-rectal Cancer.
Study Start Date : February 2006
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Liver transplantation Procedure: Liver transplantation and colo-rectal cancer
Liver transplantation


Outcome Measures

Primary Outcome Measures :
  1. Survival [ Time Frame: 6 years ]

Secondary Outcome Measures :
  1. Time to progression side-effects [ Time Frame: 6 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Colo-rectal cancer -

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00294827


Locations
Norway
Rikshospitalet-Radiumhospitalet HF
Oslo, Norway, 0020
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Svein Dueland, MD, PhD Rikshospitalet-Radiumhospitalet RRHF
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Svein Dueland, MD PhD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT00294827     History of Changes
Other Study ID Numbers: S-05409 (SECA I)
First Posted: February 22, 2006    Key Record Dates
Last Update Posted: May 25, 2017
Last Verified: May 2017

Keywords provided by Svein Dueland, Oslo University Hospital:
Liver transplantation

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Colonic Diseases
Liver Extracts
Hematinics